Does jardiance cause weight loss
Pro Research Analysisby 
Searched over 200M research papers
Does Jardiance Cause Weight Loss?
Introduction to Jardiance and Its Mechanism of Action
Jardiance, known generically as empagliflozin, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used primarily for the treatment of type 2 diabetes mellitus (T2DM). This medication works by inhibiting the reabsorption of glucose in the renal tubules, which promotes the excretion of glucose through urine (glucosuria). This mechanism not only helps in reducing blood glucose levels but also has additional metabolic effects .
Weight Loss Effects of Jardiance
Caloric Loss and Weight Reduction
One of the notable effects of Jardiance is its ability to promote weight loss. The excretion of glucose through urine results in a loss of calories, which contributes to weight reduction. Clinical trials have demonstrated that patients taking empagliflozin experience a significant reduction in body weight. On average, patients can expect to lose approximately 2 kilograms over a period of 24 to 104 weeks .
Mechanisms Behind Weight Loss
The weight loss observed with Jardiance is primarily due to the caloric loss associated with glucosuria. Additionally, the osmotic diuresis effect of the drug, which leads to the excretion of excess fluid, may also contribute to a reduction in body weight. This dual mechanism makes Jardiance an effective option for weight management in patients with T2DM Scheen2015Arun2022.
Comparative Efficacy
Comparison with Other Antidiabetic Medications
When compared to other antidiabetic medications such as metformin, glimepiride, or sitagliptin, empagliflozin not only provides similar glycemic control but also offers the added benefit of weight reduction. This makes it a preferable choice for patients who are also looking to manage their weight alongside controlling their blood sugar levels .
Additional Benefits
Cardiovascular and Renal Protection
Beyond weight loss, Jardiance has been shown to offer cardiovascular protection, as evidenced by the EMPA-REG OUTCOME trial. It also has renoprotective effects, making it a comprehensive treatment option for patients with T2DM .
Conclusion
In summary, Jardiance (empagliflozin) is an effective SGLT2 inhibitor that not only helps in managing blood glucose levels but also promotes weight loss through caloric loss and osmotic diuresis. Clinical trials have consistently shown a reduction in body weight, making it a valuable option for patients with type 2 diabetes who are also concerned about weight management. Additionally, its cardiovascular and renal protective effects further enhance its therapeutic profile Scheen2015Arun2022.
Sources and full results
Most relevant research papers on this topic